Ipsen S.A. (0MH6.IL)

113,80 +1,80 (+1,61%) In data: 03:28PM BST. Mercato aperto.

Ipsen S.A.

65, quai Georges Gorse
Boulogne-Billancourt 92100
France
33 1 58 33 50 00
https://www.ipsen.com

Settore/i: Healthcare
Settore: Drug Manufacturers - Specialty & Generic
Impiegati a tempo pieno: 5.300

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Mr. David Loew	MD, CEO & Director	2,22M	N/D	1967
Mr. Aymeric Le Chatelier	Exec. VP & Group CFO	N/D	N/D	1969
Dr. Aidan Murphy Ph.D.	Exec. VP of Technical Operations	N/D	N/D	1966
Mr. Craig Marks	Vice-Pres of Investor Relations	N/D	N/D	N/D
Mr. Francois Garnier	Exec. VP of Legal Affairs, Gen. Counsel & Chief Bus. Ethics Officer	N/D	N/D	1962
Ms. Gwenan White	Exec. VP of Communications, Public Affairs & Sustainability	N/D	N/D	N/D
Mr. Regis Mulot	Exec. VP & Chief HR Officer	N/D	N/D	1966
Ms. Dominique Bery	Head of Nordics & Baltics	N/D	N/D	1971
Dr. Yan Moore M.D.	Sr. VP & Head of Oncology Therapeutic Area	N/D	N/D	1967
Dr. Alexander McEwan	Vice-Pres & Head of Radiopharmaceuticals	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2022 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in EUR.

Descrizione

Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. It offers Somatuline for neuroendocrine tumors and acromegaly; Dysport for motor muscular disorders and medical aesthetics; Decapeptyl for the treatment of advanced metastatic prostate cancer; Cabometyx for renal cell and second-line hepatocellular carcinoma; Onivyde for second-line metastatic pancreatic cancer; and Tazverik to treat third-line follicular lymphoma. The company also provides NutropinAq for growth failure in children due to growth hormone (GH) deficiency, turner syndrome or chronic renal insufficiency, and GH deficiency in adults; and Increlex for growth failure in children and adolescents. In addition, it offers Xermelo for the treatment of carcinoid syndrome; and Cometriq to treat medullary thyroid cancer. Ipsen S.A. has agreements with Debiopharm; Exelixis; Galderma; Blueprint Medicines; TerSera Therapeutics; Rhythm Pharmaceuticals; Teijin; Schwabe; BAKX Therapeutics Inc.; and Exicure. The company was founded in 1929 and is headquartered in Boulogne-Billancourt, France.

Governance aziendale

L'ISS Governance QualityScore di Ipsen S.A. al 1 ottobre 2023 è 8. I criteri di valutazione fondamentali sono revisione: 8; Consiglio di Amministrazione: 8; diritti degli azionisti: 7; retribuzione: 6.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.